---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-024011"
form_type: "8-K"
ticker: "LPCN"
cik: "0001535955"
company_name: "Lipocine Inc."
filed_at: "2025-11-18T23:59:59+00:00"
generated_at: "2026-05-16T18:46:34.184706+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lipocine reports promising interim safety for LPCN 1154 in Phase 3 PPD trial; topline Q2 2026

## Summary
- DSMB review after one-third of planned 80 participants (n=30) recommended continuation as planned without modification.
- 47 participants completed dosing with no dose reductions, discontinuations, drug-related SAEs, loss of consciousness, or excessive sedation.
- Topline results on track for Q2 2026; second DSMB and safety update targeted early Q1 2026.
- Phase 3 data expected to support 505(b)(2) NDA submission for LPCN 1154 later in 2026.
- Trial conducted entirely in outpatient setting per FDA feedback; 19 U.S. clinical sites participating.

## SEC filing metadata
- accession: 0001493152-25-024011
- form_type: 8-K
- ticker: LPCN
- cik: 0001535955
- company_name: Lipocine Inc.
- filed_at: 2025-11-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1535955/000149315225024011/0001493152-25-024011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1535955/000149315225024011/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-024011
- JSON: https://secwatch.observer/filing/0001493152-25-024011.json
- Plain text: https://secwatch.observer/filing/0001493152-25-024011.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.